CytoDyn CEO writes March 2025 letter to shareholders

CEO Jacob Lalezari wrote, “As envisioned, 2025 is unfolding to be an exciting year for CytoDyn (CYDY). On February 24, 2025, the Company announced increased survival rates in patients with metastatic Triple-Negative Breast Cancer who were treated with leronlimab in prior CytoDyn-sponsored studies. The impressive survival observations at 12, 24, and 36 months in patients who previously failed treatment in the metastatic or locally advanced setting indicate leronlimab could play a significant role as a paradigm-shifting therapeutic in oncology. Of particular interest, we identified a subgroup of these patients who remain alive and well today and currently identify as cancer-free. This is only the beginning of the Company’s 2025 oncology story… In terms of the regulatory process, I am confident that our collaborative relationship with the FDA has placed us on a positive trajectory. To accelerate progress in oncology where feasible, we’re establishing an oncology advisory board to ensure we are exploring the fastest and most responsible pathway forward… The Company continues to be on track financially and we forecast sufficient cash and drug supply on hand to advance our clinical priorities in 2025… In sum, the developments in oncology have set the stage for 2025 to be a benchmark year for CytoDyn. This is no longer a platform drug in search of an indication; we now have compelling data to support a role for leronlimab in solid-tumor oncology and are executing on that vision.”